Latest News by Industry
SAN DIEGO (AP) — SAN DIEGO (AP) — Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $176.9 million in its second quarter.
On a per-share basis, the San Diego-based company said it had a loss of $3.04.
The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of $3.23 per share.
The biopharmaceutical company posted revenue of $13.7 million in the period, which fell short of Street forecasts. Seven analysts surveyed by Zacks expected $13.9 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a MRTX">Zacks stock report on MRTX at https://www.zacks.com/ap/MRTX